This is highlighted by numerous genome-wide association studies identifying TRAF1 single-nucleotide polymorphisms as risk factors for developing RA and for predicting the clinical response to anti-TNF therapy.33 This evidence concerns the gene TRAF1 and rheumatoid arthritis.